Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.